Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies, according to a study at a large U.S. health system. The study also found a survival advantage among patients who received targeted therapies versus those who received chemotherapy alone.
Author(s): Goodman, Aaron M; Kim, Myung S; Prasad, Vinay | Abstract: Over the past decade, 2 strategies have advanced the treatment of patients with multiple…
Warm invite to come for a healthy outing in front of the Alamo, we will take in the beauty of the riverwalk and get our…
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
On February 20, 1939, the pro-Nazi German American Bund drew more than 20,000 people to a rally in Madison Square Garden.
Surveillance to learn more on the causes and risk factors associated with pregnancy-related deaths.
Although immune checkpoint inhibitor therapy has revolutionized the treatment of solid tumors, immunologically “cold” tumors remain difficult to treat. Adoptive cell therapy—particularly, tumor-infiltrating lymphocyte therapy—shows…
Concerns about some of their business models are building
In pregnant patients with von Willebrand disease who have reduced von Willebrand factor (VWF) activity but normal factor VIII activity, recombinant VWF may be considered…
Kevin O’Sullivan and Dr. Renee Hoenderkamp discuss the NHS’s controversial new breast cancer awareness campaign, which instructs GPs to use the term “chest” …
In patients with HF and ID, this meta-analysis suggests that IV iron reduces the risk of HHF but whether this is associated with a reduction…
